The effectiveness of GLP-1 agonists and DPP-4 inhibitors in reducing dementia risk in patients with T2DM, compared to each other or sulfonylureas (the most common second-line antihyperglycemic class), remains to be clarified. Here, GLP1R is linked to type 2 diabetes mellitus.